Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...
Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen ...
NEW YORK - November 7, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...
Zacks Investment Research on MSN
Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics
The upcoming report from DexCom (DXCM) is expected to reveal quarterly earnings of $0.57 per share, indicating an increase of 26.7% compared to the year-ago period. Analysts forecast revenues of $1.18 ...
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback